Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 1320Neoplasms 983Carcinoma, Non-Small-Cell Lung 858Prostatic Neoplasms 723Colorectal Neoplasms 662Lung Neoplasms 548Leukemia, Myeloid, Acute 475Neoplasm Metastasis 431Pancreatic Neoplasms 418Carcinoma, Hepatocellular 406Multiple Myeloma 397Ovarian Neoplasms 391Stomach Neoplasms 378Recurrence 365Squamous Cell Carcinoma of Head and Neck 325Melanoma 293Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Head and Neck Neoplasms 263Glioblastoma 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 233Lymphoma 227Esophageal Neoplasms 222Rectal Neoplasms 221Sarcoma 211Carcinoma, Renal Cell 203Colonic Neoplasms 193Lymphoma, Large B-Cell, Diffuse 191

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × Metastatic Gastric Adenocarcinoma × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡